OUR FUNDING
Use this space to introduce yourself and share your professional history.
Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research and increases innovation commitment within private companies.
Innovation Fund Denmark recently provided a funding of 5M DKK to Acesion to support the human Proof-of-Concept study in AF through their Innobooster Program.
UK based Wellcome Trust has provided substantial funding to Acesion Pharma in several rounds, through their Seeding Drug Discovery Initiative (SDDI) and the Translational Award program, to advance Acesion Pharma's development program aiming for an acute treatment of atrial fibrillation (AF).
About the Wellcome Trust: "the Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests".
About SEED Capital: "SEED Capital is the largest venture fund in Denmark within the pre-seed and seed segment, and specializes in identifying and developing new and innovative technology companies. SEED Capital manages both private venture capital and public funds through innovation environment, Pre-SEED Innovation. SEED Capital manages approx. 1.5 billion DKK and has about 70 companies in its portfolio".
Novo A/S is a lead investor in Acesion Pharma and invested in the company through Novo Seeds, the early stage investment arm of Novo A/S.
About Novo A/S: "Novo A/S is the holding company in the Novo Group and is responsible for the management of the assets of the Novo Nordisk Foundation. Novo A/S is a private limited liability company fully owned by the Novo Nordisk Foundation. Besides being the major shareholder in Novo Nordisk A/S and Novozymes A/S, Novo A/S provides seed and venture capital to development stage companies and takes significant ownership positions in well-established companies, within life science and biotechnology, as well as manages a broad portfolio of financial assets"
About FC Capital: "FC Capital is a China-based private equity investment firm specialized in cross-border investments in cutting-edge biopharmaceutical and healthcare innovations.
With parallel RMB and USD funds under management, FC Capital target high-qualitycompanies and serve as a patient and strategic partner to help them achieve unprecedentedlong-term success.
Broadview Ventures is a Boston based venture fund established in 2008 by the Leducq Family Trust.
About Broadview: "Broadview has as mission to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investments in and support of early stage ventures. By making funding available at a critical moment in the development of new technology, the Leducq Family Trust is taking a leadership position in venture philanthropy by finding creative ways to support translational research in order to bring the advancements of science to the care of patients".